Meeting abstracts
SID 2026
Society for Investigative Dermatology · Chicago, 13–16 May 2026
1,214 abstracts, published in JID on 21 July 2026. Their text is on the JID website.
- 0053
Transcriptomic profiling defines core bullous pemphigoid immune programs and distinct keratinocyte-based signature in immune checkpoint inhibitor–induced disease
Penner SE, Roberts BT, … senior author Mangold AR
- 0078
In vivo dermal remodeling during oncolytic viral therapy visualized by reflectance confocal microscopy
Sparkman B, Chen D, Shmuylovich L
- 0086
Prior chemotherapy exposure and prognostic markers in large cell transformation of cutaneous t-cell lymphoma
Patel JR, Lally JS, … senior author Mannava K
- 0184
Rapid paradoxical worsening after dupilumab in ICI-associated eczematous dermatitis: Two cases
Huang J, Yang J, … senior author Shen Y
- 0213
Minimal clinical benefit with immune checkpoint inhibitor monotherapy rechallenge in ICI-refractory merkel cell carcinoma: A retrospective analysis of 16 patients
Ch'en PY, Zhang Y, … senior author Nghiem P
- 0274
Cutaneous adverse events of bispecific antibody talquetamab are associated with lower all-cause mortality in multiple myeloma
Corey S, Patil MK, … senior author Chen S
- 0306
Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma
Mendez D, Hill MA, … senior author Arbesman J
- 0393
Clinical and histopathologic characterization and management of dermatologic immune-related adverse events from immune checkpoint inhibitors
Longo LO, Trieu B, … senior author Dang T
- 0421
Understanding the impact of SSRI exposure on survival in patients receiving PD-1 inhibitors
Rachofsky C, Adler R, … senior author McLellan B
- 0467
- 0506
NAV-240, an anti-OX40L/TNFα bispecific antibody, demonstrates biomarker modulation in Phase 1 randomized, double-blind studies of healthy volunteers
Archer C, Smithson G, … senior author Grebe K
- 0508
Isotretinoin and acitretin for EGFR-, MEK-, and BRAF-inhibitor associated acneiform eruptions: A 10-year multicenter retrospective analysis
Patil MK, Kanwar R, … senior author Shi CR
- 0689
The skin microbiota drives cutaneous immune checkpoint inhibitor toxicity in genetically susceptible mice
Salazar V, Espenschied S, … senior author Stappenbeck T
- 0784
Intratumoral programmed cell death protein-1 immunotherapy in combination with ablative fractional laser effectively treats murine basal cell carcinomas
Olesen UH, Johansen AZ, … senior author Haedersdal M
- 0797
- 0806
Management of basal cell carcinoma in gorlin syndrome beyond surgery and hedgehog pathway inhibitors: A systematic review
Weitzner Y, Kann R, … senior author Ciocon D
- 0845
Association of pre-treatment skeletal muscle mass with recurrence and severe immune-related adverse events in melanoma patients receiving adjuvant anti–PD-1 therapy
Yamakawa K, Kurita Y, … senior author Yamaguchi Y
- 0851
A skin-targeted autologous immunotherapy strategy to enhance melanoma immunosurveillance
Zhang Y, Feizi N, … senior author Falo LD
- 0860
Combined talimogene laherparepvec and binimetinib in patients with NRAS-mutated melanoma induces anti-tumor immunity
Yao T, Lui RE, … senior author Chen D
- 0861
- 0873
Molecular and immunological characterization of anti-PD-L1 response in GEMM-derived melanoma cell lines
Rajmalani B, Williams JB, … senior author Kupper T
- 0877
Pathologic features of new primary melanoma following immunotherapy for advanced melanoma
Hanrahan GB, Manos M, … senior author Tsibris H
- 0881
New primary melanomas in patients with immune checkpoint inhibitor exposure for metastatic melanoma: A 12-year retrospective study
Zhong X, Mundada M, … senior author Wei M
- 0887
Neoadjuvant immunotherapy for acral melanoma: A case series
Rachofsky C, Liu M, … senior author Saenger Y
- 0971
- 1002
A bioguided garcinia kola fraction overcomes antiviral immunity to potentiate oncolytic virotherapy in melanoma and keratinocyte carcinoma
Folahan JT, Olorundare O, Chamcheu J
- 1053
Autoantibody-inducible chimeric antigen receptors (CARs): A self-regulating immunotherapy for durable remission in pemphigus vulgaris
Frazee CS, Banciella R, … senior author Ellebrecht CT
- Late-breaking, LB1145
Real-world immune checkpoint inhibitor utilization and outcomes in Merkel cell carcinoma: a propensity score-matched analysis using the TriNetX database
Richter C, Garate D, … senior author Higgins H
- Late-breaking, LB1149
An Analysis of Chemotherapeutic & Local Treatment Avenues for Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review & Meta-Analysis
Xu J, Salazar S, … senior author Wu A
- Late-breaking, LB1218
Gene expression signatures of chemotherapy-induced alopecia for scalp cooling and control patients
Rachofsky C, Liu M, … senior author McLellan B
- Late-breaking, LB1224
Taxane-induced hair follicle damage in a murine model of chemotherapy-induced alopecia
Brooks DR, Kajioka K, Wikramanayake TC
That's every abstract.